140 related articles for article (PubMed ID: 26048718)
21. T helper type 1/T helper type 17-related cytokines in chronic hepatitis C patients before and after interferon and ribavirin therapy.
Fathy A; Ahmed AS; Metwally L; Hassan A
Med Princ Pract; 2011; 20(4):345-9. PubMed ID: 21576995
[TBL] [Abstract][Full Text] [Related]
22. Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon alpha combined with paclitaxel.
Tedjarati S; Baker CH; Apte S; Huang S; Wolf JK; Killion JJ; Fidler IJ
Clin Cancer Res; 2002 Jul; 8(7):2413-22. PubMed ID: 12114447
[TBL] [Abstract][Full Text] [Related]
23. Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model.
Geller MA; Knorr DA; Hermanson DA; Pribyl L; Bendzick L; McCullar V; Miller JS; Kaufman DS
Cytotherapy; 2013 Oct; 15(10):1297-306. PubMed ID: 23993303
[TBL] [Abstract][Full Text] [Related]
24. Mouse Xenograft Model for Intraperitoneal Administration of NK Cell Immunotherapy for Ovarian Cancer.
Hermanson DL; Bendzick L; Kaufman DS
Methods Mol Biol; 2016; 1441():277-84. PubMed ID: 27177674
[TBL] [Abstract][Full Text] [Related]
25. Effect of virus-modified tumor cell extracts, autologous mononuclear cell infusions and interleukin-2 on oncolytic activity of effector cells of patients with advanced ovarian cancer.
Furukawa K; Lotzová E; Freedman RS; Bowen JB; Edwards CL; Wharton JT
Cancer Immunol Immunother; 1989; 30(2):126-32. PubMed ID: 2598179
[TBL] [Abstract][Full Text] [Related]
26. Ex vivo cytokine activation of peripheral blood stem cells: a potential role for adoptive cellular immunotherapy.
Meehan KR; Wu A; Hassan R; Miao Y; Chawla J; Slack R; Gehan E; Herscowitz HB
J Hematother Stem Cell Res; 2001 Apr; 10(2):283-90. PubMed ID: 11359675
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
Ettinghausen SE; Rosenberg SA
Cancer Res; 1986 Jun; 46(6):2784-92. PubMed ID: 3486038
[TBL] [Abstract][Full Text] [Related]
28. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma.
Sparano JA; Fisher RI; Sunderland M; Margolin K; Ernest ML; Sznol M; Atkins MB; Dutcher JP; Micetich KC; Weiss GR
J Clin Oncol; 1993 Oct; 11(10):1969-77. PubMed ID: 8410122
[TBL] [Abstract][Full Text] [Related]
29. Antitumor efficacy induced by human ovarian cancer cells secreting IL-21 alone or combination with GM-CSF cytokines in nude mice model.
Dou J; Wang Y; Wang J; Zhao F; Li Y; Cao M; Hu W; Hu K; He XF; Chu L; Jiang C; Gu N
Immunobiology; 2009; 214(6):483-92. PubMed ID: 19389515
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic effect of recombinant human tumor necrosis factor in ovarian carcinoma xenograft in nude mice.
Manetta A; Podczaski E; Zaino RJ; Satyaswaroop PG
Gynecol Oncol; 1989 Sep; 34(3):360-4. PubMed ID: 2504653
[TBL] [Abstract][Full Text] [Related]
31. Increased Th1, Th17 and pro-fibrotic responses in hepatitis C-infected patients are down-regulated after 12 weeks of treatment with pegylated interferon plus ribavirin.
Jimenez-Sousa MA; Almansa R; de la Fuente C; Caro-Paton A; Ruiz L; Sanchez-Antolín G; Gonzalez JM; Aller R; Alcaide N; Largo P; Resino S; de Lejarazu RO; Bermejo-Martin JF
Eur Cytokine Netw; 2010 Jun; 21(2):84-91. PubMed ID: 20483710
[TBL] [Abstract][Full Text] [Related]
32. Induction of endogenous cytokine-mRNA in circulating peripheral blood mononuclear cells by IL-2 administration to cancer patients.
Kasid A; Director EP; Rosenberg SA
J Immunol; 1989 Jul; 143(2):736-9. PubMed ID: 2661690
[TBL] [Abstract][Full Text] [Related]
33. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
34. Efficient inhibition of ovarian cancer by recombinant CXC chemokine ligand 10 delivered by novel biodegradable cationic heparin-polyethyleneimine nanogels.
Yang F; Gou M; Deng H; Yi T; Zhong Q; Wei Y; Zhao X
Oncol Rep; 2012 Aug; 28(2):668-76. PubMed ID: 22684947
[TBL] [Abstract][Full Text] [Related]
35. Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C.
Zeuzem S; Yoshida EM; Benhamou Y; Pianko S; Bain VG; Shouval D; Flisiak R; Rehak V; Grigorescu M; Kaita K; Cronin PW; Pulkstenis E; Subramanian GM; McHutchison JG
Hepatology; 2008 Aug; 48(2):407-17. PubMed ID: 18666223
[TBL] [Abstract][Full Text] [Related]
36. Recombinant adeno-associated virus 2-mediated antiangiogenic prevention in a mouse model of intraperitoneal ovarian cancer.
Isayeva T; Ren C; Ponnazhagan S
Clin Cancer Res; 2005 Feb; 11(3):1342-7. PubMed ID: 15709207
[TBL] [Abstract][Full Text] [Related]
37. Comparison of pegylated interferon α-2b plus psoralen PUVA versus standard interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma.
Hüsken AC; Tsianakas A; Hensen P; Nashan D; Loquai C; Beissert S; Luger TA; Sunderkötter C; Schiller M
J Eur Acad Dermatol Venereol; 2012 Jan; 26(1):71-8. PubMed ID: 22168776
[TBL] [Abstract][Full Text] [Related]
38. Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN.
De Cesare M; Sfondrini L; Campiglio M; Sommariva M; Bianchi F; Perego P; van Rooijen N; Supino R; Rumio C; Zunino F; Pratesi G; Tagliabue E; Balsari A
J Immunother; 2010 Jan; 33(1):8-15. PubMed ID: 19952960
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy in liver tumors: II. Intratumoral injection with activated tumor-infiltrating lymphocytes, intrasplenic administration of recombinant interleukin-2 and interferon alpha causes tumor regression and lysis.
Liu DL; Håkansson CH; Seifert J
Cancer Lett; 1994 Sep; 85(1):39-46. PubMed ID: 7923100
[TBL] [Abstract][Full Text] [Related]
40. Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group study.
Clark JI; Mehrabi J; Sosman JA; Logan TF; Margolin KA; Dutcher JP; Urba WJ; Ernstoff MS; McDermott DF; Lau AM; Atkins MB
J Immunother; 2007; 30(8):839-46. PubMed ID: 18049336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
